

Sino Biological Company Profile

Sino Biological, Inc. (“Sino Bio” or the “Company”) is a global leading provider of biological research reagents and related contract research services. The Company is headquartered in Beijing, China, and has established subsidiaries in the US, Germany, and Japan. Sino Bio became a public company in August 2021, when it successfully completed an IPO on the stock exchange ChiNext, a subsidiary of the Shenzhen Stock Exchange (Sino Biological, 301047).

The Company offers a vast portfolio of about 6,500 recombinant proteins, 14,000 antibodies, 47,000 genes, and multiple serum-free mammalian cell culture media products. These reagents are used by over 7,000 customers from pharmaceutical and biotechnology companies to research institutions in over 90 countries and regions worldwide. Sino Bio’s proprietary technology platforms also enable customized end-to-end solutions for customers with complex protein and antibody needs.

Led by a group of experienced scientists, the Company is constantly striving for growth, quality, and innovation. Sino Bio’s team is continuously growing and currently has over 900 members, among whom a third have masters or doctoral-level degrees. In recent years, the Company has expanded to over 346,000 square feet, including 268,000 square feet of R&D and production facilities and over 78,000 square feet of GMP-level manufacturing workshops and laboratories, where over 2,000 new protein and antibody products are developed every year. Many of these new products are best-in-class on the market, including GMP-grade cytokines, enzymes and kinases, and full-length multi-transmembrane proteins. The Company has also achieved ISO9001, ISO13485, and CNAS quality system certifications.

Sino Bio has long been recognized for its contribution to the field of infectious disease research. The Company’s Provir™ reagent collection is the world’s leading viral antigen bank, featuring thousands of antigens and antibodies covering a wide range viral types including influenza, RSV, and coronavirus strains. Many of these reagents have been used to manufacture rapid antigen and antibody diagnostic tests around the globe. In addition, the Company has received CiteAb’s “Supplier Succeeding in SARS-COV-2 Research” and “Protein Supplier to Watch” awards for two consecutive years.

Sino Bio aims to advance life science and improve human health through the provision of superior quality research reagents and CRO services. The Company will continue to develop new products to address the unmet needs and demands from today’s biomedical research community.